3 weeks Wall Street Analysts See a 136.83% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?Zacks
The mean of analysts’ price targets for Day One Biopharmaceuticals (DAWN) points to a 136.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
X